Physician profile
Lee S Simon
NPI 1457494932
$600,300.73
in general payments reported to CMS, 2019-2025
17 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237K · 2020: $86K · 2021: $101K · 2022: $92K · 2023: $51K · 2024: $14K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Honoraria: $3,210 · Travel and Lodging: $778 · Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,089.65 |
| Honoraria | $3,210.00 |
| Travel and Lodging | $777.87 |
| Food and Beverage | $336.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $340,667.91 | 2019-2023 | Krystexxa, Tepezza |
| Pfizer INC. | $60,750.00 | 2019-2023 | |
| Boehringer Ingelheim International Gmbh | $56,504.40 | 2019-2022 | |
| Teikoku Pharma USA, INC. | $25,618.25 | 2023-2025 | Lidoderm, Dexmedetomidine |
| Eli Lilly and Company | $20,943.65 | 2019-2021 | |
| Lilly USA, LLC | $18,920.58 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18,357.25 | 2022-2025 | Exparel, Iovera, Zilretta |
| Strongbridge US INC. | $16,589.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $8,729.49 | 2020-2023 | |
| Emd Serono, INC. | $7,475.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $7,298.10 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $6,770.62 | 2022-2023 | Lupkynis |
| Abbvie INC. | $5,418.75 | 2023-2025 | Rinvoq |
| Autolus INC | $2,889.68 | 2025 | |
| Pacira Therapeutics, INC. | $1,687.50 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,650.00 | 2022-2023 | |
| Tonix Medicines, INC. | $30.13 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.